Vivek Subbiah: Forward-thinking journal on AI in Oncology and precision medicine

Vivek Subbiah shared on X/Twitter:

Just in time for the holidays. Nice to get the print edition and preview issue of AI in Precision Oncology – new journal.
Forward-thinking journal on AI in Oncology and precision medicine.
Delighted to be on the editorial board of this newly launched journal with Nikhil Thaker, Blythe Adamson, Ezra Cohen, Arturo LoAIza-Bonilla, Douglas Flora, and many more amazing colleagues.

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.